Go Pro
→ Ready to give options a try? Your first trade (Ticker included) -INSIDE (From Base Camp Trading) (Ad)tc pixel Free HBP Stock Alerts

Helix BioPharma (HBP) Competitors

Helix BioPharma logo
C$1.85 -0.20 (-9.76%)
As of 03:59 PM Eastern
Compare

HBP vs. PLI, ABCN, TH, BCT, and SCYB

Should you buy Helix BioPharma stock or one of its competitors? Helix BioPharma's main competitors and comparable companies include ProMetic Life Sciences (PLI), VIVO Cannabis (ABCN), Theratechnologies (TH), BriaCell Therapeutics (BCT), and Scythian Biosciences (SCYB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Helix BioPharma compare to ProMetic Life Sciences?

Helix BioPharma (TSE:HBP) and ProMetic Life Sciences (TSE:PLI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

Helix BioPharma has higher earnings, but lower revenue than ProMetic Life Sciences. Helix BioPharma is trading at a lower price-to-earnings ratio than ProMetic Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A
ProMetic Life SciencesC$39.91M0.00-C$1.47B-C$63.06N/A

ProMetic Life Sciences' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -21.54% -279.98%
ProMetic Life Sciences N/A N/A N/A

0.0% of Helix BioPharma shares are held by institutional investors. 2.2% of Helix BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Helix BioPharma had 1 more articles in the media than ProMetic Life Sciences. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for ProMetic Life Sciences. Helix BioPharma's average media sentiment score of 0.75 beat ProMetic Life Sciences' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the media.

Company Overall Sentiment
Helix BioPharma Positive
ProMetic Life Sciences Neutral

Summary

Helix BioPharma beats ProMetic Life Sciences on 6 of the 10 factors compared between the two stocks.

How does Helix BioPharma compare to VIVO Cannabis?

VIVO Cannabis (CVE:ABCN) and Helix BioPharma (TSE:HBP) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

0.0% of Helix BioPharma shares are held by institutional investors. 2.2% of Helix BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VIVO CannabisN/AN/AN/AN/AN/A
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A

VIVO Cannabis' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
VIVO CannabisN/A N/A N/A
Helix BioPharma N/A -21.54%-279.98%

In the previous week, Helix BioPharma had 1 more articles in the media than VIVO Cannabis. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for VIVO Cannabis. Helix BioPharma's average media sentiment score of 0.75 beat VIVO Cannabis' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the news media.

Company Overall Sentiment
VIVO Cannabis Neutral
Helix BioPharma Positive

Summary

Helix BioPharma beats VIVO Cannabis on 4 of the 6 factors compared between the two stocks.

How does Helix BioPharma compare to Theratechnologies?

Helix BioPharma (TSE:HBP) and Theratechnologies (TSE:TH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

In the previous week, Helix BioPharma and Helix BioPharma both had 1 articles in the media. Helix BioPharma's average media sentiment score of 0.75 beat Theratechnologies' score of 0.67 indicating that Helix BioPharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Helix BioPharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Theratechnologies
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Theratechnologies has higher revenue and earnings than Helix BioPharma. Helix BioPharma is trading at a lower price-to-earnings ratio than Theratechnologies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A
TheratechnologiesC$84.38M2.44-C$1.96M-C$0.19N/A

0.0% of Helix BioPharma shares are held by institutional investors. Comparatively, 0.5% of Theratechnologies shares are held by institutional investors. 2.2% of Helix BioPharma shares are held by insiders. Comparatively, 1.2% of Theratechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Helix BioPharma has a beta of 0.433836, meaning that its share price is 57% less volatile than the broader market. Comparatively, Theratechnologies has a beta of 0.256166, meaning that its share price is 74% less volatile than the broader market.

Helix BioPharma has a net margin of 0.00% compared to Theratechnologies' net margin of -9.67%. Theratechnologies' return on equity of 36.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -21.54% -279.98%
Theratechnologies -9.67%36.00%5.15%

Summary

Theratechnologies beats Helix BioPharma on 6 of the 11 factors compared between the two stocks.

How does Helix BioPharma compare to BriaCell Therapeutics?

Helix BioPharma (TSE:HBP) and BriaCell Therapeutics (CVE:BCT) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Helix BioPharma is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A
BriaCell TherapeuticsN/AN/AN/A-C$0.38N/A

In the previous week, Helix BioPharma had 1 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for BriaCell Therapeutics. Helix BioPharma's average media sentiment score of 0.75 beat BriaCell Therapeutics' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the media.

Company Overall Sentiment
Helix BioPharma Positive
BriaCell Therapeutics Neutral

0.0% of Helix BioPharma shares are owned by institutional investors. 2.2% of Helix BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

BriaCell Therapeutics' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -21.54% -279.98%
BriaCell Therapeutics N/A N/A N/A

Summary

Helix BioPharma beats BriaCell Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Helix BioPharma compare to Scythian Biosciences?

Helix BioPharma (TSE:HBP) and Scythian Biosciences (CVE:SCYB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Helix BioPharmaN/AN/A-C$50.55M-C$0.04N/A
Scythian BiosciencesN/AN/AN/AN/AN/A

Scythian Biosciences' return on equity of 0.00% beat Helix BioPharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Helix BioPharmaN/A -21.54% -279.98%
Scythian Biosciences N/A N/A N/A

0.0% of Helix BioPharma shares are held by institutional investors. 2.2% of Helix BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Helix BioPharma had 1 more articles in the media than Scythian Biosciences. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for Scythian Biosciences. Helix BioPharma's average media sentiment score of 0.75 beat Scythian Biosciences' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the media.

Company Overall Sentiment
Helix BioPharma Positive
Scythian Biosciences Neutral

Summary

Helix BioPharma beats Scythian Biosciences on 4 of the 6 factors compared between the two stocks.

Get Helix BioPharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for HBP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HBP vs. The Competition

Export
MetricHelix BioPharmaBiotechnology IndustryHealthcare SectorTSE Exchange
Market CapC$141.30MC$4.03BC$7.26BC$12.57B
Dividend Yield1.50%3.60%2.53%6.25%
P/E Ratio-46.2512.66273.2839.47
Price / SalesN/A1,309.16613.489.82
Price / Cash11.32106.8777.8282.29
Price / Book9.6216.2912.894.71
Net Income-C$50.55M-C$22.72MC$3.47BC$299.09M
7 Day Performance-2.63%-1.37%-0.33%-1.21%
1 Month PerformanceN/A11.07%6.51%4.89%
1 Year Performance36.03%53.71%25.19%28.63%

Helix BioPharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HBP
Helix BioPharma
N/AC$1.85
-9.8%		N/A+53.0%C$141.30MN/AN/A9
PLI
ProMetic Life Sciences
N/AN/AN/AN/AC$317.06MC$39.91MN/A487
ABCN
VIVO Cannabis
N/AC$1.32
+5.6%		N/A+0.0%C$256.62MN/AN/AN/A
TH
Theratechnologies
N/AC$4.47
-4.9%		N/A+0.0%C$205.53MC$84.38MN/A103
BCT
BriaCell Therapeutics
N/AC$10.60
-3.8%		N/A+0.0%C$168.68MN/AN/A5

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:HBP) was last updated on 9/3/2026 by MarketBeat.com Staff.
From Our Partners
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
Bezos… DOOMED
A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...
Paradigm Press | Sponsoredtc pixel